

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mark R. HELLBERG et al.

Serial No: 10/775,704 (Conf. #3340)

Filed: 10 February 2004

Examiner:

Group Art Unit: 1632

FOR: USE OF COMPOUNDS FOR TREATING CONDITIONS RESULTING FROM
INJURY TO THE CORNEAL NERVE AFTER LASIK AND OTHER OCULAR
SURGERIES OR TRAUMA**INFORMATION DISCLOSURE STATEMENT PURSUANT
TO 37 C.F.R. 1.56, 1.97, AND 1.98**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the non-patent literature in accordance with 37 CFR 1.98(a)(2).

A copy of the International Search Report issued in the PCT application, of which the present application is a 35 U.S.C. §371 application, is also included for the Examiner's convenience.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

By: Teresa J. Schultz
Teresa J. Schultz
Registration No. 40,256
(817) 551-4231

10 June 2004

Date

Address for Correspondence:
Alcon Research, Ltd.
Attn: Teresa J. Schultz
6201 S. Freeway, Mail Code Q-148
Fort Worth, TX 76134-2099

Attorney Docket No.: 2187 US F



JUN 11 2004

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. **Complete if Known**

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/775,704 (Conf #3340)
Filing Date	10 February 2004
First Named Inventor	Mark R. HELLBERG et al.
Art Unit	1632
Examiner Name	
Attorney Docket Number	2187 US F

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
	A4	WO 00/32197 A1	06/08/2000	Alcon Labs	
	A5	WO 01/85152 A2	11/15/2001	Alcon, Inc.	
	A6	WO 03/020281 A1	03/13/2003	Alcon, Inc.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND ALL COMMUNICATIONS TO PATENT FEE PAYMENT, P.O. Box 1450, Alexandria, VA 22313-1450.

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

* Did not receive any FOR



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. **Complete if Known**

Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

<p style="margin: 0;">Under the Paperwork Reduction Act of 1995, no persons are required to respond to a request for information contained in this form unless it displays a currently valid OMB control number.</p> <p style="margin: 0;">Substitute for form 1449/PTO</p> <p style="margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="margin: 0; font-size: small;">(Use as many sheets as necessary)</p>				<p>Complete if Known</p>	
				Application Number	10/775,704 (Conf #3340)
				Filing Date	10 February 2004
				First Named Inventor	Mark R. HELLBERG et al.
				Art Unit	
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	2187 US F

NON-PATENT LITERATURE DOCUMENTS

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B1	Aimone et al., "The 1•25(OH)2D3 analog CB-1093 induces nerve growth factor in non-human primate brain", SOCIETY FOR NEUROSCI. ABSTRACTS, 24:292, (1998)	
	B2	Ambrosio & Wilson, J., "Complication of Laser in situ Keratomileusis: Etiology, Prevention, and Treatment", Refractive Surgery 17:350-379 (2001)	
	B3	Anderson et al., Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve, INVEST. OPHTHALMOL., 13:771-783 (1974)	
	B4	Beck et al., Brain-derived neurotrophic factor protects against ischemic cell damage in the rat hippocampus, J. CEREB. BLOOD FLOW METAB., 14:689-692 (1994)	
	B5	Cellerino et al., Brain-derived neurotrophic factor/neurotrophin-4 receptor TrkB is localized on ganglion cells and dopaminergics amacrine cells in the vertebrate retina, J. COMP. NEUROL.,	
	B6	Cui et al., NT-4/5 reduces naturally occurring retinal ganglion cell death in neonatal rats, NEUROREPORT, 5:1882-1884 (1994)	
	B7	Culmsee et al., NGF antisense oligonucleotide blocks protective effects of clenbuterol against glutamate-induced excitotoxicity in vitro and focal cerebral ischemia in vivo, SOCIETY FOR NEUROSCI. ABSTRACTS, 24:295 (1998)	
	B8	De Castro et al., Corneal innervation and sensitivity to noxious stimuli in trkB knockout mice, EUR. J. NEUROSCI., 10:146-152 (1998)	
	B9	Ebadi et al., Neurotrophins and their receptors in nerve injury and repair, NEUROCHEM INT., 30:347-374 (1997)	
	B10	Gao et al., Elevated mRNA expression of brain-derived neurotrophic factor in retinal ganglion cell layer after optic nerve injury, INVEST. OPHTHALMOL. VIS. SCI., 38:1840-1847 (1997)	

Examiner Signature _____ Date Considered _____
Note: This form is for the purpose of tracking a candidate's performance and not for the purpose of tracking the candidate's progress in the program.


Signature _____ Indicate if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in con-

considered. Include copy of this form with next communication to applicant. **2** I am attaching a translation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if applicable. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

To assist you in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 5 Attorney Docket Number 2187 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Graul & Castaner, AIT-082, DRUGS OF THE FUTURE, 22:945-947 (1997)	
	C2	Grønborg et al., Neuroprotection by a novel compound, NS521, SOCIETY FOR NEUROSCI. ABSTRACTS, 24:1551 (1998)	
	C3	Jelsma et al., Different forms of the neurotrophin receptor trkB mRNA predominate in rat retina and optic nerve, J. NEUROBIOL., 24:1207-1214 (1993)	
	C4	Kaplan et al., Signal transduction by the neurotrophin receptors, CURR. OPIN. CELL BIOL., 9:213-221 (1997)	
	C5	Kirsch et al., Evidence for multiple, local functions of ciliary neurotrophic factor (CNTF) in retinal development: expression of CNTF and its receptors and in vitro effects on target cells, J. NEUROCHEM., 68:979-990 (1997)	
	C6	Lambiase et al., "Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases", INVEST. OPHTHALMOL. VIS. SCI., 39:1272-1275 (1998)	
	C7	Lambiase et al., "Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas", INVEST. OPHTHALMOL. VIS. SCI., 41:1063-1069 (2000)	
	C8	Lewin et al., Physiology of the neurotrophins, ANN. REV. NEUROSCI., 19:289-317 (1997)	
	C9	Lindholm et al., Brain-derived neurotrophic factor is a survival factor for cultured rat cerebellar granule neurons and protects them against glutamate-induced neurotoxicity, Appln EUR. J. NEUROSCI., 5:1455-1464 (1993)	
	C10	Mansour-Robaey et al., Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells, PROC. NATL. ACAD. SCI. USA, 91:1632-1636 (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Complete if Known

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

5

Application Number	10/775,704 (Conf #3340)
Filing Date	10 February 2004
First Named Inventor	Mark R. HELLBERG et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2187 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	D1	Matsui et al., Protective effects of ONO-2506 on neurological deficits and brain infarct volume following 1 week of permanent occlusion of middle cerebral artery in rats, SOCIETY FOR NEUROSCI. ABSTRACTS, 24:254 (1998)	
	D2	Mey et al., Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo, BRAIN RES., 602:304-317 (1993)	
	D3	Meyer-Franke et al., Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture, NEURON, 15:805-819 (1995)	
	D4	Nabeshima et al., Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats, GERONTOLOGY, 40(supp. 2):46-56 (1994)	
	D5	Ophthalmic Surgery: Principles of Practice, Ed., G.L. Spaeth, W.B. Sanders Co., Philadelphia, PA, U.S.A., pages 85-87 (1990)	
	D6	Quigley et al., The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve, INVEST. OPHTHALMOL., 15:606-616 (1976)	
	D7	Raff et al., Programmed cell death and the control of cell survival: lessons from the nervous system, SCIENCE, 262:695-700 (1993)	
	D8	Rickman et al., Expression of the protooncogene, trk, receptors in the developing rat retina, VIS. NEUROSCI., 12:215-222 (1995)	
	D9	Segal et al., Intracellular signaling pathways activated by neurotrophic factors, ANN. REV. NEUROSCI., 19:463-489 (1996)	
	D10	Ugolini et al., TrkA, TrkB and p75 mRNA expression is developmentally regulated in the rat retina, BRAIN RES., 704:121-124 (1995)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office
JUN 11 2004
SAC-ENT & TRADEMARKS
O I P E J C 103

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

Sheet

5

of

5

Application Number	10/775,704 (Conf #3340)
Filing Date	10 February 2004
First Named Inventor	Mark R. HELLBERG et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2187 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	E1	Unoki et al., Protection of the rat retina from ischemic injury by brain-derived neurotrophic factor, ciliary neurotrophic factor, and basic fibroblast growth factor, INVEST. OPHTHALMOL. VIS. SCI., 35:907-915 (1994)	
	E2	Weibel et al., Brain-derived neurotrophic factor (BDNF) prevents lesion-induced axonal die-back in young rat optic nerve, BRAIN RES., 679:249-254 (1995)	
	E3	Wilson, "Laser In Situ Keratomileusis-induced (Presumed) Neurotrophic Epitheliopathy", OPHTHALMOLOGY 108:1082-1087 (2001)	
	E4	Yu, SYMPOSIUM ON CATARACT, IOL AND REFRACTORY SURGERY, Abstract 263 (2000)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.